frenolicin B: produced by Streptomyces roseofulvus strain AM 3867; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 163292 |
| CHEMBL ID | 474390 |
| CHEBI ID | 48201 |
| SCHEMBL ID | 19912603 |
| MeSH ID | M0069275 |
| Synonym |
|---|
| CHEBI:48201 , |
| (3ar,5r,11br)-7-hydroxy-5-propyl-3,3a,5,11b-tetrahydro-2h-furo[3,2-b]naphtho[2,3-d]pyran-2,6,11-trione |
| frenolicin b |
| 68930-68-7 |
| bdbm29508 |
| CHEMBL474390 |
| unii-385375ge9y |
| 385375ge9y , |
| 2h-furo(3,2-b)naphtho(2,3-d)pyran-2,6,11-trione, 3,3a,5,11b-tetrahydro-7-hydroxy-5-propyl-, (3ar-(3aalpha,5alpha,11balpha))- |
| DTXSID10219000 |
| hydroxy(propyl)[?]trione |
| SCHEMBL19912603 |
| Q27121079 |
| (11r,15r,17r)-4-hydroxy-17-propyl-12,16-dioxatetracyclo[8.7.0.03,8.011,15]heptadeca-1(10),3(8),4,6-tetraene-2,9,13-trione |
| AT33736 |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| benzoisochromanequinone | A class of Streptomyces aromatic polyketide antibiotics. |
| p-quinones | A quinone in which the two oxo groups of the quinone are located para to each other on the 6-membered quinonoid ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAC-alpha serine/threonine-protein kinase | Homo sapiens (human) | IC50 (µMol) | 0.2267 | 0.0002 | 0.7387 | 10.0000 | AID1061208; AID1799010; AID414794; AID719902 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID719902 | Inhibition of human AKT1 using biotinylated GSKalpha peptide (SGRARTSSFA) as a substrate after 1 hr | 2012 | Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14 | Irreversible protein kinase inhibitors: balancing the benefits and risks. |
| AID414795 | Cytotoxicity against human MDA468 cells expressing AKT | 2009 | Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8 | Pyranonaphthoquinone lactones: a new class of AKT selective kinase inhibitors alkylate a regulatory loop cysteine. |
| AID763026 | Cytotoxicity against human A549 cells after 2 days by MTT assay | 2013 | Journal of natural products, Aug-23, Volume: 76, Issue:8 | Frenolicins C-G, pyranonaphthoquinones from Streptomyces sp. RM-4-15. |
| AID414794 | Inhibition of AKT | 2009 | Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8 | Pyranonaphthoquinone lactones: a new class of AKT selective kinase inhibitors alkylate a regulatory loop cysteine. |
| AID1061208 | Inhibition of AKT1 (unknown origin) by high-throughput screen assay | 2014 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1 | Preparation and evaluation of deconstruction analogues of 7-deoxykalafungin as AKT kinase inhibitors. |
| AID1799010 | Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer Lance Assay from Article 10.1021/jm900075g: \\Pyranonaphthoquinone lactones: a new class of AKT selective kinase inhibitors alkylate a regulatory loop cysteine.\\ | 2009 | Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8 | Pyranonaphthoquinone lactones: a new class of AKT selective kinase inhibitors alkylate a regulatory loop cysteine. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (11.11) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.12) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (5.56%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (94.44%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||